Title: | Using macrophage activation to augment immunotherapy of established tumours | ||||
Journal: | British Journal of Cancervolume | ||||
Year: | 2013 | ||||
Abstract | In several different murine models of immunotherapy for lung cancer, DMXAA-induced macrophage activation significantly augmented the therapeutic effects of immunotherapy. By increasing influx of neutrophils and anti-tumour (M1) macrophages to the tumour, DMXAA altered myeloid cell phenotypes, thus changing the intratumoural M2/non-M2 TAM immunoinhibitory ratio. It also altered the tumour microenvironment to be more pro-inflammatory. Modulating macrophages during immunotherapy resulted in increased numbers, activity, and antigen-specificity of intratumoural CD8+ T cells. Macrophage depletion reduced the effect of combining immunotherapy with macrophage activation, supporting the importance of TAMs in the combined effect. | ||||
Cite/Figure | |||||
Links | https://www.nature.com/articles/bjc201393(如需全文,請聯(lián)系我們) |
獨家代理
中國大陸地區(qū)
生產(chǎn)廠家
歐洲荷蘭王國
獨家代理
香港臺灣澳門
Copyright ? 2004-2023 靶點科技(北京)有限公司. 版權(quán)所有. 京ICP備18027329號-1